 ADELAIDE, Australia, Aug. 31, 2022 GLOBE NEWSWIRE -- Bionomics Limited ASX:BNO Nasdaq: BNOX Bionomics or Company, a clinical-stage biopharmaceutical company developing novel, allosteric ion channel modulators designed to transform the lives of patients suffering from serious central nervous system CNS disorders with high unmet medical need, today announced that it will participate in the following upcoming investor conferences in September: 